Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
BioNexus Gene Lab Corp. (BGLC) had Return on Tangible Equity of -8.02% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$2.14M |
|
$-0.62M |
|
$1.79M |
|
$0.34M |
|
$2.76M |
|
$-0.62M |
|
$-0.00M |
|
$-0.62M |
|
$-0.62M |
|
$-0.62M |
|
$-0.62M |
|
$-0.62M |
|
$-0.62M |
|
$-0.59M |
|
$-0.55M |
|
17.97M |
|
17.97M |
|
$-0.04 |
|
$-0.04 |
|
| Balance Sheet Financials | |
$6.54M |
|
$1.52M |
|
$2.94M |
|
$9.48M |
|
$1.56M |
|
-- |
|
$0.15M |
|
$1.71M |
|
$7.77M |
|
$7.77M |
|
$7.77M |
|
17.97M |
|
| Cash Flow Statement Financials | |
$-0.82M |
|
$-0.02M |
|
$-0.00M |
|
$2.89M |
|
$2.09M |
|
$-0.80M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.19 |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
16.07% |
|
-28.94% |
|
-27.83% |
|
-- |
|
-29.17% |
|
-29.17% |
|
$-0.83M |
|
-- |
|
-- |
|
-- |
|
0.23 |
|
1.52 |
|
1.21 |
|
74.45 |
|
-8.02% |
|
|
Return on Tangible Equity |
-8.02% |
-6.58% |
|
-8.02% |
|
$0.43 |
|
$-0.05 |
|
$-0.05 |
|